TipHub

₹34.6

▼ -0.4 -1.14%

As of 06 Nov 2026 · delayed

NSE Listed

ESM · ESM 1
What does ESM · ESM 1 mean?
NSE · Enhanced Surveillance Measure (ESM 1)ESM is the micro/small-cap ramp brake: it fires when a sub-₹1000cr stock's price variation is extreme versus its peer universe, or it's loss-making with a stretched valuation. Practical meaning: intraday speculation is shut off (Trade-for-Trade — every purchase must be taken to delivery), margins go to 100%, and at Stage II price discovery moves to periodic call auctions inside a 2% band.Criteria: Micro / small-cap companies (main-board market-cap below ₹500 cr) shortlisted on objective price parameters — high-low price variation, close-to-close price variation and standard deviation. Stage I = 100% margin + a ≤5% price band + Trade-for-Trade; Stage II = a 2% price band + periodic call auction.Exchange notice · 2026-08-06

Onyx Biotec Limited (ONYX)

Volume: 12,000Avg Vol 1W: 7,600Avg Vol 1M: 10,40052W Range:₹24.2₹49.65
NSE BSE www.onyxbiotec.com AI Report
Key Ratios
Checked 8h ago
Market Cap—
Current Price₹34.6
Previous Close₹35
High / Low (52w)₹49.65 / ₹24.2
Volume12,000
Avg Vol (1W)7,600
Avg Vol (1M)10,400
Stock P/E21.25
Book Value₹30.56
Dividend Yield—
ROE—
ROA—
Revenue (TTM)₹70 Cr
Revenue Growth—
Profit Margin—
Total Debt—
Shares Outstanding—
Face Value—
EPS (TTM)₹-0.12
P/B1.13
Debt / Equity0.25
50 DMA₹38.69
200 DMA₹37.09
Day change-1.14%
SurveillanceESM · ESM 1
Price Chart
₹34.6▼ 11.28% · 1Y
₹48₹2923.8L
2025-11-06
2026-11-06

20-day avg volume: 10K shares

Pros
  • Company is almost debt-free.
  • Revenue grew 14% YoY.
  • Net profit is growing year over year.
Profit & Loss (Annual)
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹45 Cr₹40 Cr₹54 Cr₹63 Cr₹70 Cr
EBITDA₹4 Cr₹3 Cr₹7 Cr₹8 Cr₹1 Cr
Net Profit₹3 Cr₹2 Cr₹4 Cr₹5 Cr₹0 Cr
EPS2.841.563.053.31-0.12
Balance Sheet
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹37 Cr₹59 Cr₹74 Cr₹91 Cr₹95 Cr
Total Liabilities₹20 Cr₹41 Cr₹49 Cr₹36 Cr₹40 Cr
Equity₹16 Cr₹18 Cr₹25 Cr₹56 Cr₹55 Cr
Total Debt—————
Cash Flow
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹0 Cr₹2 Cr₹2 Cr₹1 Cr₹-1 Cr
Investing₹-6 Cr₹-23 Cr₹-3 Cr₹1 Cr₹-5 Cr
Financing₹5 Cr₹16 Cr₹3 Cr₹5 Cr₹2 Cr
Free Cash Flow₹0 Cr₹2 Cr₹2 Cr₹1 Cr₹-1 Cr
Shareholding
Promoter 41.74% Institutions 2.61% Public 55.64%
Efficiency & Working Capital
ROCE12.2%
Interest Coverage0.7
Dividend Payout—
Debtor Days144 d
Inventory Days74 d
Payable Days93 d
Cash Conversion Cycle126 d
Working Capital Days218 d
Shareholding Details

As of 2026-09-30

Promoter41.7%
FII0.2%
DII2.4%
Institutions2.6%
Public55.6%
Promoter Pledge0%
No. of Shareholders631
Shareholding Pattern

Quarterly — figures in %. Latest 6 quarters.

PeriodNov 2024Nov 2024Mar 2025Sept 2025Mar 2026Sept 2026
Promoters65.1%65.1%65.1%65.1%65.1%41.7%
FIIs8.7%8.7%5.4%2%1.1%0.2%
DIIs0%0%0%0%2.4%2.4%
Public26.1%26.1%29.5%33%31.4%55.6%
Promoter Pledge0%0%0%0%0%0%
No. of Shareholders1,1811,181551640586631
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Naresh KumarShareholding of Promoter and Promoter Group24%43,47,000
Kunal BhardwajPublic Shareholding15%27,22,000
Fateh Pal SinghShareholding of Promoter and Promoter Group11.6%20,97,600
Sanjay JainShareholding of Promoter and Promoter Group6.2%11,20,600
Kanhaiya BhardwajPublic Shareholding3.9%6,98,000
Tushar KinkerPublic Shareholding3.8%6,86,000
Apneet Kahlon .Public Shareholding2.5%4,50,000
Gautam BhardwajPublic Shareholding2.4%4,40,000
Invicta Continuum Fund IPublic Shareholding2.4%4,34,000
Invicta CapservPublic Shareholding1.5%2,75,000
Monika Uday ShahPublic Shareholding1.4%2,50,000
Riya ChadhaShareholding of Promoter and Promoter Group0%4,000
Ram PiariShareholding of Promoter and Promoter Group0%0
Rekha GulatiShareholding of Promoter and Promoter Group0%0
Mehak Sood WaliaShareholding of Promoter and Promoter Group0%0
Marshal AhluwaliaShareholding of Promoter and Promoter Group0%0
Rideybir Singh WaliaShareholding of Promoter and Promoter Group0%0
Sunil SoodShareholding of Promoter and Promoter Group0%0
Anu SoodShareholding of Promoter and Promoter Group0%0
Megha KarolShareholding of Promoter and Promoter Group0%0
Muskaan Handa MahajanShareholding of Promoter and Promoter Group0%0
Dev Rudra MahajanShareholding of Promoter and Promoter Group0%0
Shivaay MahajanShareholding of Promoter and Promoter Group0%0
Arun KumarShareholding of Promoter and Promoter Group0%0
Latika JainShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Sanjay JainExecutive Director & MD2025
Harsh MahajanExecutive Director / Whole Time Director / CFO2025
Naresh KumarE D & Wholetime Director2025
Lakshya JainE D & Wholetime Director2025
Parmjeet KaurNon-Exec & Non-Independent Dir2025
Prince Preet SinghIndependent Director2025
Vineet SinghIndependent Director2025
Nitesh GargIndependent Director2025
Ruchi ChowdhuryCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacturing of Pharmaceutical Pro₹0 Cr—
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10201818
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026000202
2026000101
2026000102
Company Information
Incorporated2005
AuditorR C A & Co LLP
Investor Email[email protected]
🌐 www.onyxbiotec.com ↗

📍 Bir Plassi Near Sainimajraropr, Nalagarh Rd Dist Solan, Solan, Himachal Pradesh, 174101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

One Point One Solutions Ltd.Onesource Specl Pharma LimitedOil & Natural Gas Corpn Ltd.Onix Solar Energy Ltd.OnMobile Global Ltd.Onward Technologies Ltd.Optiemus Infracom Ltd.Optimus Finance Ltd.Optimystix Entertainment India Ltd.Optivalue Tek Consulting Ltd.Orbit Exports LimitedOrchasp LimitedAll “O” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search